Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells - PubMed

Affiliations

• PMID: 17625602
• DOI: 10.1038/sj.leu.2404862

Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells

N Kato et al. Leukemia. 2007 Oct.

Abstract

Innate immune cells such as natural killer (NK) cells play a crucial role in antitumor immune responses. NKG2D is a major activating immunoreceptor expressed in not only NK cells but also CD8+ T cells and shows cytotoxicity against tumors by recognizing its ligands major histocompatibility complex class I-related chain A and B (MICA and MICB) on tumor cells. Recently, it has been suggested that NKG2D-mediated cytotoxicity correlates with the expression levels of NKG2D ligands on target cells. In this study, we were able to increase the expression levels of MICA and MICB on leukemic cell lines and patients' leukemic cells by treatment with trichostatin A (TsA), a histone deacetylase (HDAC) inhibitor. Chromatin immunoprecipitation (ChIP) assays revealed that treatment with TsA resulted in increased acetylation of histone H3 and decreased association with HDAC1 at the promoters of MICA and MICB. Intriguingly, upregulation of MICA and MICB by treatment with TsA led to enhancement of the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Our results suggest that regulation of the expression of NKG2D ligands by treatment with chromatin-remodeling drugs may be an attractive strategy for immunotherapy.

Similar articles

• Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

  Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Armeanu S, et al. Cancer Res. 2005 Jul 15;65(14):6321-9. doi: 10.1158/0008-5472.CAN-04-4252. Cancer Res. 2005. PMID: 16024634

• Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.

  Cox ST, Madrigal JA, Saudemont A. Cox ST, et al. Tissue Antigens. 2014 Sep;84(3):293-303. doi: 10.1111/tan.12400. Epub 2014 Jun 25. Tissue Antigens. 2014. PMID: 24962621

• Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.

  Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI, Rodríguez-Cortez O, Alatorre B, Pérez-Cárdenas E, Chacón-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, Contreras-Paredes A, Dueñas-González A. Chávez-Blanco A, et al. Int J Oncol. 2011 Dec;39(6):1491-9. doi: 10.3892/ijo.2011.1144. Epub 2011 Jul 26. Int J Oncol. 2011. PMID: 21805029

• MICA and MICB genes: can the enigma of their polymorphism be resolved?

  Stephens HA. Stephens HA. Trends Immunol. 2001 Jul;22(7):378-85. doi: 10.1016/s1471-4906(01)01960-3. Trends Immunol. 2001. PMID: 11429322 Review.

• The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.

  Sutherland CL, Chalupny NJ, Cosman D. Sutherland CL, et al. Immunol Rev. 2001 Jun;181:185-92. doi: 10.1034/j.1600-065x.2001.1810115.x. Immunol Rev. 2001. PMID: 11513139 Review.

Cited by

• BCL11B regulates MICA/B-mediated immune response by acting as a competitive endogenous RNA.

  Qian M, Geng J, Luo K, Huang Z, Zhang Q, Zhang JA, Ji L, Wu J. Qian M, et al. Oncogene. 2020 Feb;39(7):1514-1526. doi: 10.1038/s41388-019-1083-0. Epub 2019 Oct 31. Oncogene. 2020. PMID: 31673069

• Molecular Bases for the Regulation of NKG2D Ligands in Cancer.

  Huergo-Zapico L, Acebes-Huerta A, López-Soto A, Villa-Álvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Huergo-Zapico L, et al. Front Immunol. 2014 Mar 21;5:106. doi: 10.3389/fimmu.2014.00106. eCollection 2014. Front Immunol. 2014. PMID: 24711808 Free PMC article. Review.

• Nitroglycerin: a comprehensive review in cancer therapy.

  Meunier M, Yammine A, Bettaieb A, Plenchette S. Meunier M, et al. Cell Death Dis. 2023 May 12;14(5):323. doi: 10.1038/s41419-023-05838-5. Cell Death Dis. 2023. PMID: 37173331 Free PMC article. Review.

• Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression.

  Xia C, Liu C, He Z, Cai Y, Chen J. Xia C, et al. J Exp Clin Cancer Res. 2020 Jul 6;39(1):127. doi: 10.1186/s13046-020-01627-6. J Exp Clin Cancer Res. 2020. PMID: 32631421 Free PMC article.

• Regulation of immune responses by histone deacetylase inhibitors.

  Licciardi PV, Karagiannis TC. Licciardi PV, et al. ISRN Hematol. 2012;2012:690901. doi: 10.5402/2012/690901. Epub 2012 Mar 18. ISRN Hematol. 2012. PMID: 22461998 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program
  • National BioResource Project

• Miscellaneous

  • NCI CPTAC Assay Portal